Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine

Spine

Volumn 36, Issue 17, 2011, Pages

  Zhang, Wei ^a   Zhang, Yuming ^a   Li, Pengfei ^a   Rhodesm, Steven D ^b   Wang, Yunxia ^a   Xue, Xingkui ^b   Dong, Yuchang ^a   Ding, Wenyuan ^a   Shen, Yong ^a   Zhang, Biao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonate; giant cell tumor; sodium ibandronate; spine

Indexed keywords

IBANDRONIC ACID;

ADULT; ARTICLE; BONE GRAFT; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GIANT CELL TUMOR; HUMAN; LUMBAR SPINE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PRIORITY JOURNAL; REOPERATION; SPINE TUMOR;

ADULT; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GIANT CELL TUMORS; HUMANS; SPINAL NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051547891     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3182127f91     Document Type: Article

References (36)

1. Campanacci M, Baldini N, Boriani S, et al. Giant-cell tumor of bone. J Bone Joint Surg Am 1987; 69: 106-14. (Pubitemid 17030377)
2. Zheng MH, Robbins P, Xu J, et al. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001; 16: 297-307. (Pubitemid 32094046)
3. Robinson D, Einhorn TA. Giant cell tumor of bone: a unique para-digm of stromal-hematopoietic cellular interactions. J Cell Biochem 1994; 55: 300-3. (Pubitemid 24218804)
4. Arpornchayanon O'Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thai 2008; 91: 1609-12.
5. Tse LF, Wong KC, Kumta SM, et al. Bisphosphonates reduce lo-cal recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008; 42: 68-73 (Pubitemid 350297173)
6. Shimada Y, Hongo M, Miyakoshi N, et al. Giant cell tumor of fi fth lumbar vertebrae: two case reports and review of the literature. Spine J 2007; 7: 499-505. (Pubitemid 47040665)
7. Cheng YY, Huang L, Lee KM, et al. Bisphosphonates induce apop-tosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004; 75: 71-7. (Pubitemid 38989221)
8. Khan DC, Malhotra S, Stevens RE, et al. Radiotherapy for the treatment of giant cell tumor of the spine: a report of six cases and review of the literature. Cancer Invest 1999; 17: 110-13. (Pubitemid 29115642)
9. Chen ZX, Gu DZ, Yu ZH, et al. Radiation therapy of giant cell tumor of bone: analysis of 35 patients. Int J Radiat Oncol Biol Phys 1986; 12: 329-34. (Pubitemid 16108858)
10. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, et al. Two modes of action of bisphosphonates on osteoclastic re-sorption of mineralized matrix. Bone Miner 1986; 1: 27-39. (Pubitemid 16018095)
11. Bidwell JK, Young JW, Khalluff E. Giant cell tumor of the spine: computed tomography appearance and review of the literature. J Comput Tomogr 1987; 11: 307-11. (Pubitemid 17130174)
12. Murphey MD, Andrews CL, Flemming DJ, et al. From the archives of the AFIP. Primary tumors of the spine: radiologic pathologic correlation. Radiographics 1996; 16: 1131-58. (Pubitemid 126448475)
13. Kwon JW, Chung HW, Cho EY, et al. MRI fi ndings of giant cell tumors of the spine. AJR Am J Roentgenol 2007; 189: 246-50. (Pubitemid 46983220)
14. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005; 90: 494-9. (Pubitemid 40627446)
15. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am 2005; 87: 1609-18. (Pubitemid 40917766)
16. Hart RA, Boriani S, Biagini R, et al. A system for surgical staging and management of spine tumors. A clinical outcome study of giant cell tumors of the spine. Spine 1997; 22: 1773-82.
17. Chow LT, Kumta SM. Massive intestinal hemorrhage resulting from a polypoid tumor in the sigmoid colon: an unusual com-plication of a giant cell tumor of the fi fth lumbar vertebra. Spine 2003; 28: 121-4.
18. Shimizu K, Ido K, Fujio K. Total spondylectomy and spinal shorten-ing for giant-cell tumour of spine. Lancet 1996; 348: 342. (Pubitemid 26254654)
19. Weinstein JN, McLain RF. Primary tumors of the spine. Spine 1987; 12: 843-51. (Pubitemid 18031908)
20. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-9. (Pubitemid 28163009)
21. Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97: 840-7. (Pubitemid 36125821)
22. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecu-lar mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961-78. (Pubitemid 30413179)
23. Chang SS, Suratwala SJ, Jung KM, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res 2004; 426: 103-9. (Pubitemid 39167115)
24. Wermelin K, Suska F, Tengvall P, et al. Stainless steel screws coated with bisphosphonates gave stronger fi xation and more surrounding bone. Histomorphometry in rats. Bone 2008; 42: 365-71.
25. Yang SC, Chen LH, Fu TS, et al. Surgical treatment for giant cell tu-mor of the thoracolumbar spine. Chang Gung Med J 2006; 29: 71-8
26. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007; 5: 475-82.
27. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) in-duced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-17. (Pubitemid 37064711)
28. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced ex-posed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-75.
29. Walter C, Klein MO, Pabst A, et al. Infl uence of bisphosphonates on endothelial cells, fi broblasts, and osteogenic cells. Clin Oral Investig 2010; 14: 35-41.
30. Heras P, Kritikos K, Hatzopoulos A, et al. Effi cacy of ibandro-nate for the treatment of skeletal events in patients with metastatic breast cancer. Eur J Cancer Care 2009; 18: 653-6.
31. Li M, Xing XP, Zhang ZL, et al. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteo-porotic women: a 1-year study. J Bone Miner Metab 2010; 28: 299-305.
32. Croom KF, Scott LJ. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66: 1593-603.
33. Shahnazari M, Yao W, Dai W, et al. Higher doses of bisphospho-nates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 2010; 46: 1267-74.
34. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 2005; 37: 433-40. (Pubitemid 41317315)
35. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with meta-static bone disease: results from two randomised, placebo-con-trolled phase III studies. Br J Cancer 2004; 90: 1133-7. (Pubitemid 38496803)
36. Landesberg R, Eisig S, Fennoy I, et al. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg 2009; 67: 27-34.